Fasting substrates predict chronic kidney disease progression in CREDENCE trial patients with type 2 diabetes
BACKGROUND Sodium-glucose cotransporter 2 inhibitors slow down progression of chronic kidney disease (CKD). We tested whether the circulating substrate mix is related to CKD progression and cardiovascular outcomes in patients with type 2 diabetes (T2D) and albuminuric CKD in the CREDENCE trial.METHO...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
American Society for Clinical investigation
2024-12-01
|
| Sraith: | JCI Insight |
| Ábhair: | |
| Rochtain ar líne: | https://doi.org/10.1172/jci.insight.180637 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|